SCHEDULE: Highbridge Capital Management Discloses 6.1% Stake in Annovis Bio

Highbridge Capital Management, LLC has reported beneficial ownership of 6.1% of Annovis Bio, Inc.'s common stock, primarily through exercised warrants.

Summary

• Highbridge Capital Management, LLC, acting as an investment adviser, has filed a Schedule 13G.
• The filing discloses beneficial ownership of 2,775,578 shares of Annovis Bio, Inc. common stock.
• This represents 6.1% of the class of securities.
• The shares are issuable upon the exercise of warrants held by Highbridge Funds.
• The filing is dated June 30, 2026, with the report signed on August 14, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant investment stake rather than new operational or financial performance data.

Positives

• Highbridge Capital Management, LLC has taken a significant stake, indicating confidence in Annovis Bio's future prospects.
• The 6.1% ownership stake is a substantial position, potentially signaling increased institutional interest in the company.

Negatives

• The filing does not provide any new financial performance data or operational updates for Annovis Bio.
• The ownership is based on exercised warrants, not direct ownership of existing shares, which could imply a future dilution event if warrants are exercised.

Risks

• The primary risk is that the ownership is contingent on warrant exercise, which could lead to dilution of existing shareholders if not managed carefully.
• As an investment adviser, Highbridge's investment strategy could change, leading to a sale of shares and potential downward pressure on the stock price.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Annovis Bio. It solely reports on the ownership stake of Highbridge Capital Management, LLC.

Management Comments

• The filing should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings often precede or coincide with periods of increased investor interest or strategic shifts within the biotechnology sector. This filing indicates a notable position taken by an established investment manager in Annovis Bio.

Stakeholder Impact

• Shareholders: May view the increased institutional interest positively, but should be aware of potential dilution from warrant exercises.
• Creditors: No direct impact mentioned, but increased institutional interest could indirectly support the company's financial stability.
• Employees: Indirect positive impact through potential company growth and stability driven by significant investment.

Next Steps

• Highbridge Capital Management, LLC will continue to hold and potentially manage its stake in Annovis Bio.
• Annovis Bio may see increased attention from institutional investors due to this significant stake.

Key Dates

Recommendation

The filing indicates a significant investment by Highbridge Capital Management, LLC, suggesting a level of confidence. However, without new operational or financial data from Annovis Bio, the filing primarily reflects an investment position rather than a fundamental change in the company's outlook. Therefore, a 'hold' recommendation is appropriate, pending further company disclosures.

Keywords

Annovis Bio, Highbridge Capital Management, Schedule 13G, Beneficial Ownership, Warrants, Investment Adviser, Common Stock, SEC Filing